The Current State of CRPC Management With Judd W. Moul, MD, FACS

In the past decade, much progress has been made in the management of castration-resistant prostate cancer (CRPC), with numerous new agents improving outcomes in patients with this disease. However, many challenges still remain. In this interview with i3 Health, Judd W. Moul, MD, FACS, Professor of Urologic Surgery at the Duke School of Medicine, discusses strategies that community oncologists and urologists can utilize to determine the best treatment for their patients. He also discusses the rol...
Continue reading

Castration-Resistant Prostate Cancer: Guiding Patients Through Treatment With Brenda Martone, MSN, ANP-BC, AOCNP

​Androgen deprivation therapy is a cornerstone of treatment for progressive prostate cancer, but over time, many patients stop responding to this treatment, developing a resistance to castration. Until recently, nonmetastatic castration-resistant prostate cancer (CRPC) lacked effective treatment options; this situation has changed dramatically with the rise of several new agents. Metastatic CRPC is the primary cause of prostate-related mortality, yet advances in treatment are extending survival....
Continue reading

Educational Need in Castration-Resistant Prostate Cancer

Due to the increase in treatment options for castration-resistant prostate cancer (CRPC) in recent years, some confusion exists over the optimal therapeutic approach. A number of factors must be considered in CRPC treatment, including patient health status, rate of disease progression and disease burden, presence of bone or visceral metastases, mechanism of action and tolerability of available agents, and prior lines of therapy and response.Baseline data collected from i3 Health's continuing med...
Continue reading

Darolutamide Approved in Nonmetastatic CRPC

The FDA has now approved darolutamide (Nubeqa®, Bayer), an androgen receptor antagonist, for the treatment of nonmetastatic castration-resistant prostate cancer (CRPC).The approval was based on the ARAMIS phase 3 trial (NCT02200614), which enrolled 1,509 patients with nonmetastatic CRPC and a prostate-specific antigen doubling time of 10 months or less. Patients were randomized in a 2:1 ratio to receive darolutamide or placebo along with continued androgen deprivation therapy for a primary end p...
Continue reading

Castration-Resistant Prostate Cancer: New Developments, New Challenges With Alicia Morgans, MD, MPH

​Prostate cancer is the most common tumor type in men in the United States. Nonmetastatic castration-resistant prostate cancer (CRPC) is a highly heterogeneous disease process that lacks effective treatment options. Metastatic CRPC is the primary cause of prostate-related mortality, with a median overall survival that remains less than two years.In this interview with i3 Health, Alicia K. Morgans, MD, MPH, Associate Professor of Medicine at Northwestern University Feinberg School of Medicine, di...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.